ATRS - Antares Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
104,846
63,554
54,515
52,222
45,658
Cost of Revenue
46,079
31,065
27,466
28,817
19,458
Gross Profit
58,767
32,489
27,049
23,405
26,200
Operating Expenses
Research Development
10,751
12,328
13,147
21,127
19,732
Selling General and Administrative
58,303
36,762
30,353
26,395
26,931
Total Operating Expenses
69,054
49,090
43,500
47,522
46,662
Operating Income or Loss
-10,287
-16,601
-16,451
-24,116
-20,462
Interest Expense
3,186
2,675
1,423
-
-
Total Other Income/Expenses Net
12,885
12,761
1,131
-202
-82
Income Before Tax
-588
-6,515
-16,743
-24,239
-20,484
Income Tax Expense
-
0
0
100
175
Income from Continuing Operations
-588
-6,515
-16,743
-24,339
-20,659
Net Income
-588
-6,515
-16,743
-24,339
-20,659
Net Income available to common shareholders
-588
-6,515
-16,743
-24,339
-20,659
Reported EPS
Basic
-
-0.04
-0.11
-0.16
-0.14
Diluted
-
-0.04
-0.11
-0.16
-0.14
Weighted average shares outstanding
Basic
-
162,875
156,054
154,992
146,594
Diluted
-
162,875
156,054
154,992
146,594
EBITDA
-
-1,116
-13,216
-22,256
-18,892